Stock Scorecard



Stock Summary for Viridian Therapeutics Inc (VRDN) - $19.79 as of 11/20/2024 8:51:27 PM EST

Total Score

8 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for VRDN

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for VRDN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for VRDN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for VRDN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for VRDN (44 out of 90)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 6
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0

Latest News for for VRDN

Viridian Therapeutics, Inc. ( VRDN ) Reports Q3 Loss, Tops Revenue Estimates 11/12/2024 1:25:00 PM
MannKind ( MNKD ) Matches Q3 Earnings Estimates 11/7/2024 10:40:00 PM
Stoke Therapeutics, Inc. ( STOK ) Reports Q3 Loss, Tops Revenue Estimates 11/5/2024 1:15:00 PM
VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints 9/11/2024 3:27:00 PM
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday - Calavo Growers ( NASDAQ:CVGW ) 9/10/2024 2:07:00 PM
Why Is Viridian Therapeutics Stock Trading Higher On Tuesday? - Viridian Therapeutics ( NASDAQ:VRDN ) 9/10/2024 1:14:00 PM
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Oracle ( NYSE:ORCL ) 9/10/2024 10:41:00 AM
Viridian Therapeutics, Inc. ( VRDN ) Reports Q2 Loss, Lags Revenue Estimates 8/8/2024 1:25:00 PM
Top 3 Health Care Stocks You May Want To Dump This Quarter - Verona Pharma ( NASDAQ:VRNA ) 7/30/2024 2:13:00 PM
Strength Seen in Viridian Therapeutics ( VRDN ) : Can Its 8.7% Jump Turn into More Strength? 7/17/2024 11:01:00 AM

Financial Details for VRDN

Company Overview

Ticker VRDN
Company Name Viridian Therapeutics Inc
Country USA
Description Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. The company is headquartered in Boulder, Colorado.
Sector Name LIFE SCIENCES
Industry Name SERVICES-MEDICAL LABORATORIES
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 19.79
Price 4 Years Ago 16.45
Last Day Price Updated 11/20/2024 8:51:27 PM EST
Last Day Volume 1,027,693
Average Daily Volume 1,002,053
52-Week High 27.20
52-Week Low 11.40
Last Price to 52 Week Low 73.60%

Valuation Measures

Trailing PE N/A
Industry PE 51.15
Sector PE 40.32
5-Year Average PE -4.61
Free Cash Flow Ratio 2.08
Industry Free Cash Flow Ratio 10.25
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 18.55
Total Cash Per Share 9.51
Book Value Per Share Most Recent Quarter 6.55
Price to Book Ratio 3.08
Industry Price to Book Ratio 1.89
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 5,335.05
Industry Price to Sales Ratio Twelve Trailing Months 1.70
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 10
Analyst Strong Buy Ratings 5

Share Statistics

Total Shares Outstanding 79,213,000
Market Capitalization 1,567,625,270
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -83.05%
Reported EPS 12 Trailing Months -4.32
Reported EPS Past Year -2.96
Reported EPS Prior Year -5.32
Net Income Twelve Trailing Months -257,084,000
Net Income Past Year -237,734,000
Net Income Prior Year -129,874,000
Quarterly Revenue Growth YOY 19.40%
5-Year Revenue Growth -56.41%
Operating Margin Twelve Trailing Months -970.70

Balance Sheet

Total Cash Most Recent Quarter 753,200,000
Total Cash Past Year 477,400,000
Total Cash Prior Year 424,600,000
Net Cash Position Most Recent Quarter 735,713,000
Net Cash Position Past Year 457,195,000
Long Term Debt Past Year 20,205,000
Long Term Debt Prior Year 4,645,000
Total Debt Most Recent Quarter 17,487,000
Equity to Debt Ratio Past Year 0.96
Equity to Debt Ratio Most Recent Quarter 0.98
Total Stockholder Equity Past Year 442,022,000
Total Stockholder Equity Prior Year 395,064,000
Total Stockholder Equity Most Recent Quarter 707,496,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -197,432,000
Free Cash Flow Per Share Twelve Trailing Months -2.49
Free Cash Flow Past Year -185,068,000
Free Cash Flow Prior Year -94,635,000

Options

Put/Call Ratio 0.09
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.42
MACD Signal 0.53
20-Day Bollinger Lower Band 10.12
20-Day Bollinger Middle Band 18.96
20-Day Bollinger Upper Band 27.81
Beta 1.11
RSI 46.17
50-Day SMA 17.69
150-Day SMA 19.79
200-Day SMA 19.15

System

Modified 11/19/2024 3:48:29 PM EST